Dupixent (dupilumab)

pCPA File Number: 22214
Negotiation Status:
Concluded with an LOI
Indication(s):
Atopic dermatitis
Sponsor/Manufacturer:
Sanofi-Aventis Canada Inc.
CDA-AMC Project Number:
SF0754-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: